Sanofi Management

Management criteria checks 4/4

Sanofi's CEO is Paul Hudson, appointed in Sep 2019, has a tenure of 5.67 years. total yearly compensation is €9.95M, comprised of 14.1% salary and 85.9% bonuses, including company stock and options. directly owns 0.011% of the company’s shares, worth $14.29M. The average tenure of the management team and the board of directors is 5.2 years and 5.1 years respectively.

Key information

Paul Hudson

Chief executive officer

€10.0m

Total compensation

CEO salary percentage	14.1%
CEO tenure	5.7yrs
CEO ownership	0.01%
Management average tenure	5.2yrs
Board average tenure	5.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Paul Hudson's remuneration changed compared to Sanofi's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2025	n/a	n/a	€6b
Dec 31 2024	€10m	n/a	€5b
Sep 30 2024	n/a	n/a	€5b
Jun 30 2024	n/a	n/a	€4b
Mar 31 2024	n/a	n/a	€5b
Dec 31 2023	€11m	€1m	€5b
Sep 30 2023	n/a	n/a	€9b
Jun 30 2023	n/a	n/a	€9b
Mar 31 2023	n/a	n/a	€8b
Dec 31 2022	€11m	€1m	€8b
Sep 30 2022	n/a	n/a	€6b
Jun 30 2022	n/a	n/a	€7b
Mar 31 2022	n/a	n/a	€7b
Dec 31 2021	€11m	€1m	€6b
Sep 30 2021	n/a	n/a	€6b
Jun 30 2021	n/a	n/a	€6b
Mar 31 2021	n/a	n/a	€12b
Dec 31 2020	€11m	€1m	€12b
Sep 30 2020	n/a	n/a	€11b
Jun 30 2020	n/a	n/a	€11b
Mar 31 2020	n/a	n/a	€3b
Dec 31 2019	€6m	€433k	€3b

Compensation vs Market: Paul's total compensation ($USD11.20M) is about average for companies of similar size in the US market ($USD14.40M).

Compensation vs Earnings: Paul's compensation has been consistent with company performance over the past year.

CEO

Paul Hudson (57 yo)

5.7yrs

Tenure

€9,951,047

Compensation

Mr. Paul Hudson serves as Chief Executive Officer of Sanofi at Hoechst Pakistan Limited (formerly known as sanofi-aventis Pakistan Limited). He has been Chief Executive Officer at Sanofi since September 1,...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Paul Hudson	CEO & Director	5.7yrs	€9.95m	0.011% $ 14.3m
François-Xavier Roger	Executive VP & CFO	1.1yrs	no data	no data
Madeleine Roach	Executive VP & Head of Business Operations	1.6yrs	no data	no data
Laurent Gilhodes	Principal Accounting Officer and Vice President of Corporate Accounting	no data	no data	no data
Josephine Fubara	Chief Science Officer of Consumer Health Care	no data	no data	no data
Thomas Larsen	Head of Investor Relations	1.3yrs	no data	no data
Dante Beccaria	Global Compliance Officer & VP	13.1yrs	no data	no data
Roy Papatheodorou	Executive VP & General Counsel	3.3yrs	no data	no data
Pierre Chancel	Senior Vice President of Global Diabetes and Senior Vice President of Global Marketing	20.8yrs	no data	no data
Natalie Bickford	Executive VP & Chief People Officer	4.8yrs	no data	no data
Marie-Hélène Laimay	Senior Vice President of Audit & Internal Control Assessment	23yrs	no data	no data
Olivier Charmeil	Executive Vice President of General Medicines	19.3yrs	no data	no data

5.2yrs

Average Tenure

57yo

Average Age

Experienced Management: SNYN.F's management team is seasoned and experienced (5.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Paul Hudson	CEO & Director	5.6yrs	€9.95m	0.011% $ 14.3m
Jean-François Dehecq	Honorary Chairman	15yrs	€4.71m	no data
Serge Weinberg	Honorary Chairman	2yrs	€324.96k	0% $ 0
Patrick Kron	Independent Director	11yrs	€195.00k	0.000080% $ 101.9k
Lise Kingo	Independent Director	5.1yrs	€167.50k	0.000080% $ 101.9k
Frederic Oudea	Independent Chairman	2yrs	€884.84k	0.000080% $ 101.9k
Fabienne Lecorvaisier	Independent Director	12yrs	€170.25k	0.000080% $ 101.9k
Rachel Duan	Independent Director	5.1yrs	€145.50k	0.000080% $ 101.9k
Carole Ferrand	Independent Director	3yrs	€197.75k	0.000080% $ 101.9k
Barbara Lavernos	Director	4.1yrs	€156.50k	0.000080% $ 101.9k
Clotilde Delbos	Independent Director	1.1yrs	€124.50k	0.000040% $ 50.9k
Christophe Babule	Director	6.3yrs	€162.00k	0.000080% $ 101.9k

5.1yrs

Average Tenure

60yo

Average Age

Experienced Board: SNYN.F's board of directors are considered experienced (5.1 years average tenure).

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/11 01:43
End of Day Share Price	2025/05/09 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sanofi is covered by 63 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kamla Singh	AlphaValue
John Eade	Argus Research Company
Odile Rundquist	Baader Helvea Equity Research

Sanofi Management

Management criteria checks 4/4

Key information

Recent management updates

Sanofi Appoints Clotilde Delbos as Chairwoman of the Compensation Committee

Sanofi, Annual General Meeting, Apr 30, 2025

Sanofi Announces Board Changes

Recent updates

Sanofi Appoints Clotilde Delbos as Chairwoman of the Compensation Committee

Clayton, Dubilier & Rice Fund XII a fund managed by Clayton, Dubilier & Rice, LLC acquired 50% stake in Opella Healthcare Group SAS from Sanofi (ENXTPA:SAN) for around €10 billion.

Sanofi's Respiratory Pipeline Advances with New Data in Asthma and Plans for New Clinical Studies in COPD

Sanofi Announces Tolebrutinib Phase 3 Data Published in NEJM Demonstrate Benefit on disability Progressive Forms

Regeneron Pharmaceuticals, Inc. and Sanofi Announce Ministry of Health, Labour and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab)

Sanofi Announces Tolebrutinib Regulatory Submission Accepted for Priority Review in the US for Patients with Multiple Sclerosis

Sanofi Adopts FDA-Selected Flu Strains to Ensure Readiness for the 2025-26 Flu Season

Sanofi, Annual General Meeting, Apr 30, 2025

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Dupixent Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented At Aad

Sanofi Announces New Duvakitug Data Reinforce Best-In-Class Potential in Ulcerative Colitis and Crohn's Disease

Sanofi Announces Sarclisa Approval in Japan for Patients with Newly Diagnated Multiple Myeloma

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

Sanofi Announces Update on E.Mbrace Phase 3 Clinical Study

Sanofi Reports Consolidated Impairment of Intangible Assets for the Fourth Quarter Ended December 31, 2024

Sanofi Announces Sarclisa Approval in the EU as the First Anti-CD38 Therapy in Combination with Standard-Of-Care VRd to Treat Transplant-ineligible Newly Diagnated Multiple Myeloma

Sanofi Announces Sarclisa Obtains First Approval in China for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma

Sanofi Announces Board Changes

Sanofi Announces Two Combination Vaccine Candidates for Prevention of Influenza and COVID-19 Granted Fast Track Designation in the US

Frantz Law Group Files Oceanside Unified School District Lawsuit Against Eli Lily, Novo Nordisk, Sanofi, Express Scripts, CVS Caremark, and Optum RX for Insulin Pricing Scheme

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Review the Resubmission of the Supplemental Biologics License Application for Dupixent®?

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis

Sanofi Announces Beyfortus (Nirsevimab) to Be Broadly Available for Babies Born in Ontario, Quebec, Nunavut, Northwest Territories, and the Yukon This Fall

Sanofi Reportedly in Talks with French Government over Opella Sale

Clayton, Dubilier & Rice Reportedly Nears €15 Billion Deal for Sanofi Consumer Health Unit

Sanofi Healthcare Bidders Reportedly Revising Offers over Talc Concerns

Sanofi Reportedly Seeks Revised Proposals for Opella

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Sanofi to Report Q2, 2025 Results on Jul 31, 2025

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Approves Dupixent (Dupilumab) as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps

Sanofi Announces Tolebrutinib Meet Primary Endpoints in HERCULES Phase 3 Study

Teva Pharmaceuticals and Sanofi Announce Accelerated Timeline for Anti-TL1A Phase 2b Program in Patients with Inflammatory Bowel Disease

Sanofi Ships U.S. Influenza Vaccines for the 2024/25 Season

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Sanofi to Present New Data from its Hemophilia Portfolio at the 32nd Congress of the International Society on Thrombosis and Haemostasis

Innate Pharma and Sanofi Shares Updated Results from the Sanofi Developed Blood Cancer Phase 1/2 1/2 SAR443579/IPH6101 Trial

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

Sanofi S.A. and Sobi Announce Once-Weekly ALTUVIIIO Approved in Japan as A New Class of Factor VIII Therapy for Hemophilia A

SK Bioscience and Sanofi Announce Positive Results from Phase II Study of 21-Valent Pneumococcal Conjugate Vaccine Candidate

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources